Valacyclovir Pregnancy and Breastfeeding Warnings
Valacyclovir is also known as: Valtrex
Valacyclovir Pregnancy Warnings
Valacyclovir has been assigned to pregnancy category B by the FDA. High-dose animal studies have failed to reveal evidence of teratogenicity. No significant neonatal toxicity or fetal drug accumulation was noted in a small pharmacokinetic study (n=20) of valacyclovir (500 mg twice daily) administered beginning at 36 weeks' gestation. Records from the Acyclovir in Pregnancy Registry regarding the outcomes of live births in 380 women exposed to systemic acyclovir during the first trimester of pregnancy demonstrated no significant increase in the frequency of birth defects over that of the general population. However, the small size of the registry precludes any definitive conclusions to be made regarding the safety of acyclovir or valacyclovir use during pregnancy. Valacyclovir should only be given during pregnancy when the need has been clearly established.
Valacyclovir Breastfeeding Warnings
The U.S. Public Health Service Centers for Disease Control and Prevention advise HIV-infected women not to breast-feed to avoid postnatal transmission of HIV to a child who may not yet be infected.
Acyclovir is excreted into breast milk after valacyclovir administration. A pharmacokinetic study (n=5) revealed that after a 500 mg dose of valacyclovir, the peak acyclovir breast milk concentrations (Cmax) were 0.5 to 2.3 times the maternal serum Cmax. The breast milk area under the concentration-time curve (AUC) for acyclovir was 1.4 to 2.2 times the maternal serum AUC. Therefore, a 500 mg maternal dose of valacyclovir would result in a 0.6 mg/kg/day dosage of acyclovir to the nursing infant (approximately 2% of a standard neonatal IV dose). No unchanged valacyclovir was detected in infant urine or maternal breast milk or serum. The manufacturer recommends that valacyclovir be administered to breast-feeding women with caution and only when clearly needed. However, HIV-infected mothers should not breast-feed their infants due to the risk of transmission of HIV via breast milk.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.